09 Jul, 2025

Sustained efficacy of Abilify Asimtufii

Dr Ilan Melnick discusses his experience with Abilify Asimtufii lasting the full two-month dosing interval in practice.

The views and opinions expressed in this video do not necessarily reflect those of Lundbeck and Otsuka.

Page: AU-ABAS-0070. July 2025. Copy: AU-ABAS-0060. June 2025. Video: AU-ABAS-0057. June 2025.

  • Body

    Abilify Asimtufii PBS Information: Authority required (STREAMLINED) Code: 16456 for Schizophrenia. This product is not listed on the PBS for the treatment of Bipolar I disorder

  • Body

    Please review Approved Product Information before prescribing. Product Information is available here or by calling Lundbeck on 1300 721 277

    Abilify Asimtufii® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Level 2/9 Help St, Chatswood NSW 2067, Abilify Asimtufii® is co-commercialised by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Ltd.

    .

Related

GO TO

Contributor

Dr Ilan Melnick
Passageway Residences of Miami-Dade County

BROUGHT TO YOU BY

Lundbeck
© 2022 Lundbeck Australia

LUNDBECK AUSTRALIA PRODUCTS

Privacy and disclaimer

Cookies

Contact Us

Lundbeck Australia Pty Ltd 
1 Innovation road, Ground floor
NSW 2113, North Ryde, Australia
Phone +61 2 8669 1000
Fax +61 2 8669 1090

 

otsuka logo

 

Otsuka Australia Pharmaceutical Pty. Ltd

subscribe newsletter

Sign up for newsletter

This website is intended for viewing only by health care professionals in Australia.

All information provided within this site is intended only for residents of Australia.